Asploro Journal of Biomedical and Clinical Case Reports
![Asploro Journal of Biomedical and Clinical Case Reports [ISSN: 2582-0370]](https://i0.wp.com/asploro.com/wp-content/uploads/2022/01/Asploro-Journal-of-Biomedical-and-Clinical-Case-Reports-Volume-5.jpg?resize=853%2C1024&ssl=1)
ISSN: 2582-0370
Article Type: Editorial
DOI: 10.36502/2022/ASJBCCR.6260
Asp Biomed Clin Case Rep. 2022 Feb 22;5(1):38-41
Hiroshi BANDO1,2*
1Tokushima University/Medical Research, Tokushima, Japan
2Japan Low Carbohydrate Diet Promotion Association, Kyoto, Japan
Corresponding Author: Hiroshi BANDO, MD, PhD, FACP ORCID iD
Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 24 January 2022; Accepted date: 15 February 2022; Published date: 22 February 2022
Citation: Bando H. Useful Oral Administration of Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA) as Semaglutide (Rybelsus) for Type 2 Diabetes Mellitus (T2DM). Asp Biomed Clin Case Rep. 2022 Feb 22;5(1):38-41.
Copyright © 2022 Bando H. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
Keywords: Semaglutide, Rybelsus, Sodium N-(8-[2-hydroxybenzoyl] amino), Peptide Innovation for Early Diabetes Treatment (PIONEER), Semaglutide Treatment Effect in People with Obesity (STEP)
Abbreviations: PIONEER: Peptide Innovation for Early Diabetes Treatment; STEP: Semaglutide Treatment Effect in People with Obesity
Abstract
As recommended pharmacological agents for type 2 diabetes mellitus (T2DM), Glucagon-Like Peptide 1 receptor agonist (GLP-1Ra) is highly evaluated for its various beneficial effects. Among them, semaglutide (Rybelsus) has been in focus for useful oral formation with useful oral hypoglycemic agent (OHA). Administration per os is possible due to the developed technique of absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate. Clinical efficacy was shown by a series of Peptide Innovation for Early Diabetes Treatment (PIONEER) with enough weight reduction and decreased HbA1c. From the results of several PIONEER programs, oral semaglutide 14 mg/day had reduced HbA1c values by approximately 1.0-1.4%.






